Small Molecule Apoptosis Inhibitors To Define The Bak Activating Switch
Funder
National Health and Medical Research Council
Funding Amount
$713,687.00
Summary
Tissue loss due to excessive apoptosis is a contributing factor to organ transplant failure and other diseases characterised by too much cell death. Using an innovative cell-based screening approach, we have identified a first in class series of molecules that potently block cell death driven by the apoptosis effector Bak. By unravelling the molecular target of our unique inhibitors and characterising their mode of action, we hope to uncover a new facet of Bax and Bak biology.
Molecular Regulation Of Apoptosis In Endothelial Cells
Funder
National Health and Medical Research Council
Funding Amount
$593,888.00
Summary
This project seeks to understand the mechanisms by which cells that make up our blood vessels are kept alive. Impaired blood vessel cell survival contributes to reduced blood vessel health, a major component of cardiovascular disease. Knowledge of how these cells are kept alive could prove useful in treating diseases affecting vessel cell survival, or potentially to combat those diseases that are caused by excessive blood vessel growth.
The Regulation And Role Of Puma And P53 In IL-3 Withdrawal Induced Cell Death
Funder
National Health and Medical Research Council
Funding Amount
$527,683.00
Summary
It is the ultimate fate of most of our cells to die by committing suicide, because they are no longer required, are no longer functioning, or are potentially harmful. This normal physiological process is termed apoptosis . When cell death fails to occur, abnormal cells can accumulate and lead to cancer. Signalling from growth-factors is required for many cell types to survive. When these signals are lost, the cells activate their cell death pathways. It is a hallmark of cancer cells that they ha ....It is the ultimate fate of most of our cells to die by committing suicide, because they are no longer required, are no longer functioning, or are potentially harmful. This normal physiological process is termed apoptosis . When cell death fails to occur, abnormal cells can accumulate and lead to cancer. Signalling from growth-factors is required for many cell types to survive. When these signals are lost, the cells activate their cell death pathways. It is a hallmark of cancer cells that they harbour mutations in cell death genes and their dependence on growth factors for survival is diminished or lost. The genes of the apoptosis pathway function either to promote or inhibit cell death. Some genes in the apoptosis pathway allow apoptosis to proceed rapidly, but do not decide the fate of the cell. Other genes are required for a cell to commit to die, and if they are mutated then a functional cell, that is capable of proliferating, survives. This is a crucial distinction because it is only the genes that decide cell fate that can act as cancer genes, and are valid targets for therapy. We have identified one particular gene, Puma, as an important regulator of cell survival. Without this gene, cells survive longer without growth-factor and, importantly, can proliferate when growth factor is restored. Understanding how this gene functions and is regulated will contribute to our understanding of the gene mutations that lead to cancer and may identify valid targets for cancer therapy. In our model we use growth factor dependent cell lines derived from mice lacking particular genes in the cell death pathway, including Puma. These cells proliferate in the presence of growth factor, and allow us to determine the role of the genes when growth factor is withdrawn. Using this system, we will determine how Puma is able to induce cell death, what other genes are required to regulate this process and how loss of Puma function may contribute to cancer development.Read moreRead less
Investigating The Role Of Mutant P53 And MCL-1 In The Sustained Growth Of MYC Lymphomas And Strategies For Targeted Therapy
Funder
National Health and Medical Research Council
Funding Amount
$616,940.00
Summary
A large number of human cancers have abnormal expression of a protein called MYC, leading to rapid growth. We found that when another protein called MCL-1 was inactivated, the lymphomas regressed. Importantly, mutations in the tumour suppressor gene called p53 are frequently found in cancer cells and we noticed that this could reduce the dependency on MCL-1. We aim to investigate this further in this grant proposal, in part using a novel drug that targets MCL-1.
Elucidating The Mechanism And Function Of Extracellular Vesicle Formation During Cell Death
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
In humans, billions of cells will die daily as part of normal turnover in various organs. It is vital that dying cells are rapidly removed as their accumulation has been linked to autoimmunity and inflammation. To aid efficient removal of dead cells, dying cells can disassemble into smaller fragments for neighbouring cells to engulf. We aim to understand the machinery that control how dying cells can disassemble into smaller pieces and their function in efficient cell clearance and autoimmunity.
Developing A New Treatment Method To Prevent Lymphopenia Associated With Sepsis
Funder
National Health and Medical Research Council
Funding Amount
$435,939.00
Summary
Sepsis or blood poisoning kills more people than breast cancer, prostate cancer and HIV/AIDS combined. It has a huge economic burden, yet there is no proper diagnostics markers or treatment. One of the main reasons for sepsis-mediated mortality is lack of functioning immune system patients. We have been able to elucidate the molecular mechanism of sepsis-mediated immune cell death and through this project, we aim to develop diagnostics and therapy for treating sepsis-mediated immune suppression.